Marrone Bio Innovations (NASDAQ: MBII) is one of 27 publicly-traded companies in the “Agricultural Chemicals” industry, but how does it contrast to its competitors? We will compare Marrone Bio Innovations to related businesses based on the strength of its risk, dividends, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Valuation & Earnings

This table compares Marrone Bio Innovations and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Marrone Bio Innovations $16.95 million -$21.12 million -0.95
Marrone Bio Innovations Competitors $3.75 billion $757.16 million 14.74

Marrone Bio Innovations’ competitors have higher revenue and earnings than Marrone Bio Innovations. Marrone Bio Innovations is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Marrone Bio Innovations has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Marrone Bio Innovations’ competitors have a beta of 0.94, suggesting that their average share price is 6% less volatile than the S&P 500.

Profitability

This table compares Marrone Bio Innovations and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Marrone Bio Innovations -177.10% N/A -64.21%
Marrone Bio Innovations Competitors -379.14% -13.39% -8.46%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Marrone Bio Innovations and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marrone Bio Innovations 0 2 1 0 2.33
Marrone Bio Innovations Competitors 214 817 909 34 2.39

Marrone Bio Innovations presently has a consensus price target of $2.50, suggesting a potential upside of 125.23%. As a group, “Agricultural Chemicals” companies have a potential upside of 0.58%. Given Marrone Bio Innovations’ higher probable upside, equities analysts plainly believe Marrone Bio Innovations is more favorable than its competitors.

Insider and Institutional Ownership

39.0% of Marrone Bio Innovations shares are held by institutional investors. Comparatively, 47.5% of shares of all “Agricultural Chemicals” companies are held by institutional investors. 7.3% of Marrone Bio Innovations shares are held by insiders. Comparatively, 22.4% of shares of all “Agricultural Chemicals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Marrone Bio Innovations competitors beat Marrone Bio Innovations on 9 of the 12 factors compared.

Marrone Bio Innovations Company Profile

Marrone Bio Innovations, Inc. offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene. Its products are used in both conventional and organic crop production, and are sold to growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens and ornamental plants. It offers Regalia for large-acre row crops, such as corn and soybeans. Its pipeline of early-stage discoveries and product candidates extends across a range of product types for end markets, including herbicides, fungicides, nematicides, insecticides, algaecides (for algae control), molluscicides (for mussel and snail control), and plant growth and plant stress regulators. It is engaged in developing MBI-010, MBI-110, Haven (MBI-505) and MBI-601.

Receive News & Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related companies with MarketBeat.com's FREE daily email newsletter.